Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics (RAPT) Income from Continuing Operations (2020 - 2023)

Historic Income from Continuing Operations for Therapeutics (RAPT) over the last 4 years, with Q4 2023 value amounting to -$33.2 million.

  • Therapeutics' Income from Continuing Operations fell 3596.25% to -$33.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$127.1 million, marking a year-over-year decrease of 4809.95%. This contributed to the annual value of -$127.1 million for FY2023, which is 4809.95% down from last year.
  • Per Therapeutics' latest filing, its Income from Continuing Operations stood at -$33.2 million for Q4 2023, which was down 3596.25% from -$33.9 million recorded in Q3 2023.
  • In the past 5 years, Therapeutics' Income from Continuing Operations ranged from a high of -$12.4 million in Q2 2020 and a low of -$33.9 million during Q3 2023
  • In the last 4 years, Therapeutics' Income from Continuing Operations had a median value of -$18.8 million in 2021 and averaged -$20.9 million.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first crashed by 1622.97% in 2022, then plummeted by 5646.74% in 2023.
  • Quarter analysis of 4 years shows Therapeutics' Income from Continuing Operations stood at -$12.7 million in 2020, then crashed by 40.79% to -$17.9 million in 2021, then plummeted by 36.27% to -$24.4 million in 2022, then tumbled by 35.96% to -$33.2 million in 2023.
  • Its Income from Continuing Operations stands at -$33.2 million for Q4 2023, versus -$33.9 million for Q3 2023 and -$28.4 million for Q2 2023.